These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 17175310

  • 1. Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function.
    Kovarik JM, Tedesco-Silva H, Lorber MI, Foster C.
    Transplant Proc; 2006 Dec; 38(10):3479-82. PubMed ID: 17175310
    [Abstract] [Full Text] [Related]

  • 2. FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study.
    Tedesco-Silva H, Lorber MI, Foster CE, Sollinger HW, Mendez R, Carvalho DB, Shapiro R, Rajagopalan PR, Mayer H, Slade J, Kahan BD, FTY720A2202 clinical study group.
    Clin Transplant; 2009 Dec; 23(5):589-99. PubMed ID: 19719728
    [Abstract] [Full Text] [Related]

  • 3. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients.
    Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM.
    Transplantation; 2010 Jul 15; 90(1):31-7. PubMed ID: 20517177
    [Abstract] [Full Text] [Related]

  • 4. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships.
    Kovarik JM, Snell GI, Valentine V, Aris R, Chan CK, Schmidli H, Pirron U.
    J Heart Lung Transplant; 2006 Apr 15; 25(4):440-6. PubMed ID: 16563975
    [Abstract] [Full Text] [Related]

  • 5. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.
    Salvadori M, Scolari MP, Bertoni E, Citterio F, Rigotti P, Cossu M, Dal Canton A, Tisone G, Albertazzi A, Pisani F, Gubbiotti G, Piredda G, Busnach G, Sparacino V, Goepel V, Messa P, Berloco P, Montanaro D, Veroux P, Federico S, Bartezaghi M, Corbetta G, Ponticelli C.
    Transplantation; 2009 Nov 27; 88(10):1194-202. PubMed ID: 19935373
    [Abstract] [Full Text] [Related]

  • 6. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J, RAD A2420 Study Group.
    Transplantation; 2009 Jul 15; 88(1):69-76. PubMed ID: 19584683
    [Abstract] [Full Text] [Related]

  • 7. Everolimus in pediatric de nova renal transplant patients.
    Hoyer PF, Ettenger R, Kovarik JM, Webb NJ, Lemire J, Mentser M, Mahan J, Loirat C, Niaudet P, VanDamme-Lombaerts R, Offner G, Wehr S, Moeller V, Mayer H, Everolimus Pediatric Study Group.
    Transplantation; 2003 Jun 27; 75(12):2082-5. PubMed ID: 12829916
    [Abstract] [Full Text] [Related]

  • 8. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M, Gerbeau C, Cambon N, Boger R, Rordorf C, Everolimus Phase 2 Study Group.
    Clin Pharmacol Ther; 2001 Jan 27; 69(1):48-56. PubMed ID: 11180038
    [Abstract] [Full Text] [Related]

  • 9. Clinical experience with Certican (everolimus) in de novo heart transplant patients at the Deutsches Herzzentrum Berlin.
    Lehmkuhl H, Hetzer R.
    J Heart Lung Transplant; 2005 Apr 27; 24(4 Suppl):S201-5; discussion S210-1. PubMed ID: 15774323
    [Abstract] [Full Text] [Related]

  • 10. Everolimus versus azathioprine in a cyclosporine and ketoconazole-based immunosuppressive therapy in kidney transplant: 3-year follow-up of an open-label, prospective, cohort, comparative clinical trial.
    Gonzalez F, Espinoza M, Herrera P, Rocca X, Reynolds E, Lorca E, Roessler E, Hidalgo J, Espinoza O.
    Transplant Proc; 2010 Apr 27; 42(1):270-2. PubMed ID: 20172327
    [Abstract] [Full Text] [Related]

  • 11. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
    Iaria G, Pisani F, Iorio B, Lucchesi C, De Luca L, Ielpo B, D'Andria D, Tariciotti L, Tisone G.
    Transplant Proc; 2006 May 27; 38(4):1018-9. PubMed ID: 16757249
    [Abstract] [Full Text] [Related]

  • 12. Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: Philippine experience.
    Li JT, Danguilan RA, Cabanayan-Casasola CB, Talusan-Tomacruz Y, Ona ET.
    Transplant Proc; 2008 Sep 27; 40(7):2211-3. PubMed ID: 18790195
    [Abstract] [Full Text] [Related]

  • 13. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
    Roos M, Liu S, Strobl M, Schmaderer C, Baumann M, Heemann U, Lutz J.
    Transplant Proc; 2008 Dec 27; 40(10):3731-6. PubMed ID: 19100477
    [Abstract] [Full Text] [Related]

  • 14. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M, Wasler A, Prenner G, Stiegler P, Stadlbauer V, Schwarz M, Tscheliessnigg K.
    Transpl Immunol; 2006 Jun 27; 16(1):46-51. PubMed ID: 16701176
    [Abstract] [Full Text] [Related]

  • 15. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul 27; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.
    Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Quéré S, Di Giambattista F, Cassuto E, RAD A2420 Study Group.
    Transpl Int; 2010 Nov 27; 23(11):1084-93. PubMed ID: 20500493
    [Abstract] [Full Text] [Related]

  • 17. Conversion to everolimus in maintenance patients--current clinical strategies.
    Pohanka E.
    Nephrol Dial Transplant; 2006 Jul 27; 21 Suppl 3():iii24-9. PubMed ID: 16815853
    [Abstract] [Full Text] [Related]

  • 18. Late acute cardiac allograft rejection: new therapeutic options?
    Schweiger M, Wasler A, Prenner G, Tripolt M, Schwarz M, Tscheliessnigg KH.
    Transplant Proc; 2005 Dec 27; 37(10):4528-31. PubMed ID: 16387161
    [Abstract] [Full Text] [Related]

  • 19. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness.
    Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, Shaw LM, Munir L, Ulbricht B, Cooper M, CRADUS09 Study Group.
    Transplantation; 2008 Mar 27; 85(6):821-6. PubMed ID: 18360262
    [Abstract] [Full Text] [Related]

  • 20. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year.
    Ettenger R, Hoyer PF, Grimm P, Webb N, Loirat C, Mahan JD, Mentser M, Niaudet P, Offner G, Vandamme-Lombaerts R, Hexham JM, Everolimus Pediatric Study Group.
    Pediatr Transplant; 2008 Jun 27; 12(4):456-63. PubMed ID: 18466433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.